Grey Zone Lymphoma (GZL)
Grey zone lymphoma (GZL) is a challenging and relatively rare subtype of lymphoma that exhibits intermediate features between different types of lymphomas. At our company, we are dedicated to advancing the development of effective drugs and therapies for GZL. With our extensive expertise in lymphoma research, we offer specialized GZL therapy development services.
Introduction to GZL
Grey zone lymphoma (GZL), also known as gray zone lymphoma, is a subtype of lymphoma that poses diagnostic challenges due to its overlapping characteristics with other types of lymphomas. The incidence of the disease is currently unknown. GZL typically presents with features transitional between these lymphoma types, making accurate classification difficult. It presents diagnostic difficulties due to its overlapping characteristics, making it crucial to develop effective drugs and therapies targeting this specific disease.
Pathogenesis of GZL
Gene expression profiling studies have revealed distinct gene signatures in GZL, demonstrating similarities with classical Hodgkin lymphoma and DLBCL. These signatures suggest downregulation of BCR pathway signaling, activation of the cytokine-JAK-STAT pathway, constitutive NF-kappa B activation, overexpression of TNF family members, high expression of extracellular matrix elements, and aberrant activation of the P13K/AKT pathway.
Furthermore, genetic studies have identified gains and breaks in specific genomic regions, such as the REL and JAK2 loci, as well as CIITA rearrangements. These genetic alterations may play a role in the development and progression of GZL.
Fig.1 Characterization of the GZL spectrum. (Sarkozy, Clémentine, et al., 2020)Targets of GZL Therapy Development
- NF-kappa B pathway: Constitutive activation of the NF-kappa B pathway has been observed in GZL. Targeting this pathway could potentially disrupt the survival and growth of GZL cells.
- BCR pathway: Downregulation of the BCR pathway signaling has been implicated in GZL. Targeting components of this pathway may offer therapeutic opportunities.
- Cytokine-JAK-STAT pathway: Aberrant activation of the cytokine-JAK-STAT pathway has been observed in GZL. Inhibiting this pathway could potentially disrupt GZL cell proliferation and survival.
- Specific genetic alterations: Genetic alterations, such as gains and breaks in specific genomic regions (e.g., REL and JAK2 loci) and CIITA rearrangements, represent potential therapeutic targets in GZL.
Therapy Development for GZL
- Small molecule drug development, particularly the R-CHOP regimen, forms the backbone of therapy, targeting cancer cells with a combination of drugs.
- Bone marrow transplantation, both autologous and allogeneic, offers the potential for long-term remission in cases of relapse or refractory disease.
- Stem cell transplantation, utilizing the regenerative potential of stem cells, provides an alternative or complementary therapy option for GZL.
Our Services
Leveraging our state-of-the-art laboratories and advanced rare disease research platform, we undertake the development of diagnostics and diverse therapies for GZL. We are deeply involved in the research and development of bone marrow cell transplantation and stem cell transplantation protocols for GZL, exploring different sources and optimizing the transplantation process. Our multiple therapy development strategies enable us to provide the most efficient support for your GZL therapy research.
Platform Capabilities
Our company also provides preclinical research services to evaluate the safety of potential GZL therapies and perform pharmacokinetics studies. Our team is focused on developing relevant disease models, including cell-based models, organoid models, and animal models, that recapitulate the characteristics of GZL, allowing us to further evaluate the feasibility of novel therapies for you.
Animal Models of GZL
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
- Sarkozy, Clémentine, et al. "Gene expression profiling of gray zone lymphoma." Blood Advances 4.11 (2020): 2523-2535.
- Sarkozy, Clémentine, et al. "Mutational landscape of gray zone lymphoma." Blood, The Journal of the American Society of Hematology 137.13 (2021): 1765-1776.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.